In September, a group of Danish investigators published in the JAMA Psychiatry an article entitled “Association of hormonal contraception with depression.”1 The authors concluded that “use of hormonal contraception, especially among adolescents, was associated with subsequent use of antidepressants and a first diagnosis of depression, suggesting depression as a potential adverse effect of hormonal contraceptive use.” The story was immediately picked up by most news outlets and spread virally. This enthusiasm occurred in spite of the fact that many earlier studies had found no association or even a reduced risk of depression symptoms.2 Some patients have started to ask again about this issue, and many more may be troubled by this new risk to their health.
Nearly 60% of women who discontinue using contraceptive implants do so because of bleeding irregularities. Counseling ahead of time can help some women better accept the bleeding and spotting, even though it does not stop their episodes. A few treatment options are recommended, such as regimens for taking combined oral contraceptives, anti-progestins, and NSAIDS. But how well do these work?
Our empirical understanding of Zika virus is rapidly evolving. This can present challenges for us as clinicians: to stay abreast of the changes and facilitate understanding and clarify implications for our patients.
The “Contraceptive Technology” conferences will help you synthesize the data and translate the evidence into clinical “pearls” you can put directly into practice. With an array of Preconferences delving into selected specialty areas of interest, plenary sessions focusing on the “hottest” topics, a thought-provoking luncheon presentation, and 30 dynamic, interactive Concurrent Sessions, including hands-on workshops…this conference is certain to improve your clinical practice and expand your network of colleagues. Read more